Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease;…
USD308.79-2.37%vs prev. close
Performance
1W
+5.78%
1M
+4.20%
3M
+9.50%
1Y
+53.82%
YTD
+67.28%
Valuation
P/E
127.0
EPS TTM
2.49
Dividend yield
—
Size and risk
Market cap
$6.3B
Beta
1.03
Price history
LGND price
USD
Total returnEventsVs index
Loading…
Next earnings
Report date
EPS estimate
Revenue estimate
Peer comparison
Ligand Pharmaceuticals
LGND
Biotechnology
Mkt cap (USD bn)
6.3
P/E
127.0
Div yld
—
1W
+5.8%
1M
+4.2%
3M
+9.5%
6M
+44.4%
1Y
+53.8%
YTD
+67.3%
Company
Ticker
Industry
Mkt cap (USD bn)
P/E
Div yld
1W
1M
3M
6M
1Y
YTD
Ligand Pharmaceuticals
LGND
Biotechnology
6.3
127.0
—
+5.8%
+4.2%
+9.5%
+44.4%
+53.8%
+67.3%
Subscribe to Equity Analytics to compare LGND with its closest peers
Sector-matched peer set with side-by-side valuation, dividend and performance over every window.